Henry Ward Wolff Net Worth

The estimated Net Worth of Henry Ward Wolff is at least $2.51 Миллион dollars as of 12 March 2019. Henry Wolff owns over 5,000 units of Sunesis Pharmaceuticals Inc stock worth over $83,875 and over the last 18 years Henry sold SNSS stock worth over $2,422,650.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Henry Wolff SNSS stock SEC Form 4 insiders trading

Henry has made over 35 trades of the Sunesis Pharmaceuticals Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Henry exercised 2,000 units of SNSS stock worth $55,100 on 3 June 2019.

The largest trade Henry's ever made was exercising 37,500 units of Sunesis Pharmaceuticals Inc stock on 11 December 2014 worth over $199,500. On average, Henry trades about 4,494 units every 38 days since 2006. As of 12 March 2019 Henry still owns at least 15,766 units of Sunesis Pharmaceuticals Inc stock.

You can see the complete history of Henry Wolff stock trades at the bottom of the page.

What's Henry Wolff's mailing address?

Henry's mailing address filed with the SEC is C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD. #200, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Sunesis Pharmaceuticals Inc

Over the last 19 years, insiders at Sunesis Pharmaceuticals Inc have traded over $89,557,714 worth of Sunesis Pharmaceuticals Inc stock and bought 191,253,594 units worth $84,730,221 . The most active insiders traders include Forest Baskett, Scott D Sandell и Peter J Barris. On average, Sunesis Pharmaceuticals Inc executives and independent directors trade stock every 67 days with the average trade being worth of $14,060,191. The most recent stock trade was executed by Tina Gullotta on 29 May 2020, trading 6,000 units of SNSS stock currently worth $1,980.

What does Sunesis Pharmaceuticals Inc do?

Complete history of Henry Wolff stock trades at Calithera Biosciences Inc, Portola Pharmaceuticals, Sangamo Therapeutics Inc и Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Inc executives and stock owners

Sunesis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Adam Craig,
  Executive Vice President - Development, Chief Medical Officer
• Stephen Ketchum,
  Director
• David Stump,
  Independent Director
• Homer Pearce,
  Independent Director
• Nicole Onetto,
  Independent Director
• Matthew Fust,
  Independent Director
• Steve Carchedi,
  Independent Director
• H. Ward Wolff,
  Director
• Tina Gullotta,
  Principal Accounting Officer, Vice President - Finance
• Dayton Misfeldt,
  Chief Executive Officer, Principal Financial Officer, Secretary, Director
• James Young,
  Non-Executive Independent Chairman of the Board
• Eric Bjerkholt,
  EVP, CFO & Corp. Secretary
• Geoffrey M. Parker,
  Director
• Steven B Ketchum,
  Director
• Daniel N Jr Swisher,
  President and CEO
• Oncology Impact Management ...,
  
• William P. Quinn,
  See Remarks
• Judith A. Fox,
  See Remarks
• Patrick J Kerins,
  10% owner
• Ryan D Drant,
  10% owner
• Forest Baskett,
  10% owner
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• Equity Opportunities Fund, ...,
  
• City Capital Llc Bay City C...,
  
• Scott D Sandell,
  10% owner
• Krishna Kittu Kolluri,
  10% owner
• Helen Susan Kim,
  Director
• Joseph I De Pinto,
  EVP, CCO
• Biopharma Partners Iii Lpal...,
  
• Equity Opportunities Fund, ...,
  
• Robert Scott Mc Dowell,
  Vice President, Research
• Edward Hurwitz,
  Director
• Dominique Semon,
  10% owner
• Biopharma Partners Iii Lpal...,
  
• Iii Eugene A Trainor,
  10% owner
• Charles M Linehan,
  10% owner
• Equity Opportunities Fund, ...,
  
• Pincus Equity Partners Lpwa...,
  
• Valerie L Pierce,
  Sr. VP, GC & Corp. Secretary
• Anthony B Evnin,
  Director
• Steven D Goldby,
  Director
• James A Wells,
  Director
• Stephen P A Fodor,
  Director
• Idec Incbiogen Idec Ma Inc ...,
  
• Pincus Equity Partners Lpwa...,
  
• Daniel C Md Adelman,
  Senior VP,Drug Discovery & Dev
• Ixmayfield Ix Management Ll...,
  
• Jonathan S Leff,
  Director
• Daryl B Winter,
  SVP,Gen Counsel/Corp Secretary
• Capital Iv, Lp Aisling Capi...,